Prostate Cancer pipeline companies are Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd., and others.
According to DelveInsight, over 140 companies are actively developing more than 150 therapies for Prostate Cancer.
Prostate Cancer Overview:
Prostate cancer occurs when cells in the prostate gland start growing uncontrollably. The disease is primarily driven by DNA mutations that trigger abnormal cell growth. Prostate cancer is often diagnosed at a later stage, once symptoms appear, but early detection is possible through screening tests before symptoms develop.
Download our report @ https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Prostate Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prostate Cancer Therapeutics Market.
Key Takeaways from the Prostate Cancer Pipeline Report
DelveInsight’s Prostate Cancer pipeline report highlights a dynamic landscape with over 140 companies actively developing more than 150 therapies for prostate cancer.
Notable recent developments include:
-
February 2025: BioXcel Therapeutics announced FDA Fast Track designation for BXCL701 with a checkpoint inhibitor to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy.
-
September 2024: Ipsen reported that the Phase III CONTACT-02 trial of Cabometyx® plus atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) met progression-free survival (PFS) endpoints, though overall survival improvement was non-significant.
-
September 2024: Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
-
July 2024: The ARANOTE trial showed that NUBEQA® plus androgen deprivation therapy (ADT) significantly improved radiological PFS in metastatic hormone-sensitive prostate cancer (mHSPC). FDA also granted Fast Track designation to SYNC-T SV-102 for mCRPC.
-
June 2024: Kangpu Biopharmaceuticals initiated a Phase II/III trial of KPG-121 with abiraterone in mCRPC.
-
May 2024: Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC.
-
April 2024: Astellas Pharma obtained European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC). FibroGen also reported positive Phase 1 results for FG-3246 in mCRPC.
Key players advancing the prostate cancer treatment landscape include Pfizer, Janssen, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas, Regeneron, Silenseed, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck, Amgen, BioNTech, Qilu Pharmaceuticals, and many others. Promising pipeline candidates include Niraparib, ZEN 3694, Ladiratuzumab, FOR46, REGN5678, and more.
Prostate Cancer Pipeline Analysis
The Prostate Cancer pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Prostate Cancer Market.
-
Categorizes Prostate Cancer therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Prostate Cancer drugs under development based on:
-
Stage of development
-
Prostate Cancer Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Prostate Cancer Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Prostate Cancer Licensing agreements
-
Funding and investment activities supporting future Prostate Cancer market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Prostate Cancer Emerging Drugs
-
Niraparib: Janssen Research & Development
-
ZEN 3694: Zenith Epigenetics
-
Ladiratuzumab vedotin: Seagen
-
FOR46: Fortis Therapeutics
-
REGN5678: Regeneron Pharmaceuticals
Prostate Cancer Companies
More than 140 companies are developing therapies for prostate cancer, with Janssen Research & Development leading the field with candidates in the advanced Phase III stage.
DelveInsight’s report covers around 150+ products under different phases of Prostate Cancer clinical trials like
-
Prostate Cancer Late stage Therapies (Phase III)
-
Prostate Cancer Mid-stage Therapies (Phase II)
-
Prostate Cancer Early-stage Therapies (Phase I)
-
Prostate Cancer Pre-clinical and Prostate Cancer Discovery stage Therapies
-
Prostate Cancer Discontinued & Inactive Therapies
Prostate Cancer pipeline report provides the Prostate Cancer therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Prostate Cancer Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Prostate Cancer Therapies and Key Prostate Cancer Companies: Prostate Cancer Clinical Trials and recent advancements
Prostate Cancer Pipeline Therapeutic Assessment
• Prostate Cancer Assessment by Product Type
• Prostate Cancer By Stage
• Prostate Cancer Assessment by Route of Administration
• Prostate Cancer Assessment by Molecule Type
Download Prostate Cancer Sample report to know in detail about the Prostate Cancer treatment market @ Prostate Cancer Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Prostate Cancer Current Treatment Patterns
4. Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prostate Cancer Late-Stage Products (Phase-III)
7. Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prostate Cancer Discontinued Products
13. Prostate Cancer Product Profiles
14. Prostate Cancer Key Companies
15. Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Prostate Cancer Unmet Needs
18. Prostate Cancer Future Perspectives
19. Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Prostate Cancer Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
